Related Experiment Video
Updated: Jul 3, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Changes in tumour biological markers during primary systemic chemotherapy (PST)
Hans Neubauer1, Christian Gall, Ulrich Vogel
1Department of Gynaecology and Obstetrics, University of Tübingen, Tübingen, Germany.
Anticancer Research
|July 18, 2008
Summary
Primary systemic therapy can alter key cancer markers like hormone receptors and Her2/neu. Re-evaluating these markers after chemotherapy is crucial for accurate patient assessment and treatment planning.
Area of Science:
- Oncology
- Molecular Pathology
- Cancer Biomarkers
Background:
- The impact of primary systemic therapy (PST) on therapeutic marker expression remains under investigation.
- Understanding these changes is vital for optimizing cancer treatment strategies.
Purpose of the Study:
- To investigate the alterations in expression of key therapeutic markers following neoadjuvant chemotherapy.
- To determine if changes in marker expression correlate with pathological response.
Main Methods:
- Analysis of baseline and post-chemotherapy biopsies from 87 patients.
- Assessed expression of oestrogen receptor (ER), progesterone receptor (PR), Bcl-2, Her2/neu, p53, and Ki-67.
- Utilized neoadjuvant anthracycline- or taxane-based chemotherapy regimens.
Main Results:
- Pathological response rate was 70%.
- Significant changes observed in hormone receptor (ER, PR) and Her2/neu status post-chemotherapy.
- Median Ki-67 index decreased significantly (30% to 13%, p<0.01).
- Only Ki-67 reduction correlated with pathological response.
Conclusions:
- Oestrogen receptor (ER), progesterone receptor (PR), and Her2/neu status require re-evaluation on post-chemotherapy specimens.
- Changes in these markers necessitate reassessment for effective treatment planning.
